Targeting on eEF2 impeded protein translation process provided a feasible strategy for the target therapy in ESCC and the proper use of TSN may be benefit for the ESCC patients in the further clinical studies. This evidence concerns the gene EEF2 and esophageal squamous cell carcinoma.